AIONCO

The mark consists of a circle which is circumscribed appearing next to the word "AIONCO" in a stylized font resembling a DNA sequence in orange and red color. Within the ring of the circle are other circles layered together with colors blue and teal. The background is transparent. White is not claimed as a color of the mark.

Mark For: AIONCO™ trademark registration is intended to cover the categories of medical testing products, namely, modified immune cells; Medical testing products, namely, modified immune cells for use in connection with various cancers with genetic treatments. [all]

>The color(s) blue, teal, orange, and red is/are claimed as a feature of the mark. The mark consists of a circle which is circumscribed appearing next to the word "AIONCO" in a stylized font resembling a DNA sequence in orange and red color. Within the ring of the circle are other circles layered together with colors blue and teal. The background is transparent. White is not claimed as a color of the mark.

Status

2021-06-30 UTC
⟳ Refresh

LIVE APPLICATION Under Examination

Research	OneLook Acronym Finder
Serial Number	88075702
Mark Literal Elements	AIONCO
Mark Drawing Type	3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S)
Mark Type	TRADEMARK. SERVICE MARK
Standard Character Claim	No
Register	PRINCIPAL
Current Location	INTENT TO USE SECTION 2020-04-02
Basis	1(b)
Class Status	ACTIVE
Primary US Classes	006: Chemicals and Chemical Compositions 018: Medicines and Pharmaceutical Preparations 044: Dental, Medical and Surgical Appliances 046: Foods and Ingredients of Foods 051: Cosmetics and Toilet Preparations 052: Detergents and Soaps
Primary International Class	005 - Primary Class (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use	No
Current Use	No
Intent To Use	Yes
Filed ITU	Yes
44D Filed	No
44E Current	No
66A Current	No
Current Basis	No
No Basis	No
Attorney Name	Don Reeve
Attorney Docket Number	68-T002
Law Office Assigned	L80
Employee Name	REINHART, MEGHAN M

Timeline

IC 005. US 006 018 044 046 051 052. G & S: Medical testing products, namely, modified immune cells; Medical testing products, namely, modified immune cells for use in connection with various cancers with genetic treatments
IC 009. US 021 023 026 036 038. G & S: Downloadable software and mobile applications for genetic assessment and identification of cancer, cancer ailments, and cancer mutations for scientific, medical, diagnostic, treatment, and research purposes, for creating local databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for creating, accessing, and using online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for recording, analyzing, storing, manipulating and organizing genetic and molecular data, and for providing access to multiple online databases that contain aggregated results of molecular biology testing and genotyping; medical testing products, namely, downloadable vaccination test forms
IC 010. US 026 039 044. G & S: Medical testing and treatment products in the form of treatment therapies, namely, apparatus for medical diagnosis, drug delivery apparatus and genetic delivery apparatus all for various cancers with genetic treatments and specimen collection tubes and containers for collecting patient specimens, namely, blood, urine, saliva, and tissue, for genomic sequencing and for detection of gene mutations, gene expression profiles or other molecular indicators or markers associated with cancer or risk of developing cancer; Medical testing and treatment product kits containing blood specimen collection tubes and containers for collecting patient blood specimens for genomic sequencing and detection of gene mutations, gene expression profiles or other molecular indicators or markers associated with cancer or risk of developing cancer modified immune cells and treatment therapies, and also containing modified immune cells, treatment therapies, test forms, mailing materials and user information inserts
IC 016. US 002 005 022 023 029 037 038 050. G & S: Medical testing and treatment products, namely, printed test forms and printed user information inserts for medical products; Medical testing products, namely, printed vaccination test forms
IC 042. US 100 101. G & S: Providing online non-downloadable software and software programs for genetic assessment and identification of cancer, cancer ailments, and cancer mutations for scientific, medical, diagnostic, treatment, and research purposes, for creating online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for creating, accessing, and using online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for recording, analyzing, storing, manipulating and organizing genetic and molecular data, and for providing access to multiple online databases that contain aggregated results of molecular biology testing and genotyping
IC 044. US 100 101. G & S: Providing medical diagnostic and treatment services, namely, tumor detection in the form of a liquid biopsy; medical diagnostic and treatment services in the nature of tumor analysis, diagnosis, and identification in the form of sequenced tissue identification, and tumor medical treatment therapy in the form of identification of appropriate combination of mutations for targeted cancers and identification of appropriate treatments targeted for those combination of mutations via modified T-Cells in the form of other treatments to inhibit expressions of those combination of mutations and to modify one or more of the mutations in the combination